Showing results (191-200 of 406) with videos related to

Sort By:
Pageof 41
Arthritis Care & Research|October 9, 2012
Leflunomide in psoriatic arthritis: results from a large European prospective observational studyFrank Behrens, Christoph Finkenwirth, Karel Pavelka, et al.
Rheumatology (Oxford, England)|October 29, 2014
Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureFrank Behrens, Juan D Cañete, Ignazio Olivieri, et al.
The Journal of Rheumatology|November 17, 2017
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the LiteratureLaure Gossec, Dennis McGonagle, Tatiana Korotaeva, et al.
Annals of the Rheumatic Diseases|February 12, 2016
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritisCharles Peterfy, Gerd R Burmester, Vivian P Bykerk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2004
Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cellsGabriela Riemekasten, Dirk Langnickel, Philipp Enghard, et al.
RMD Open|September 29, 2017
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumabGerd R Burmester, Gurjit S Kaeley, Arthur F Kavanaugh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateMark C Genovese, Josef S Smolen, Michael E Weinblatt, et al.
RMD Open|August 13, 2021
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3Daniel Aletaha, René Westhovens, Cecile Gaujoux-Viala, et al.
Annals of the Rheumatic Diseases|November 6, 2021
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 yearsKevin L Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, et al.
Annals of the Rheumatic Diseases|June 10, 2015
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Pageof 41